Posters

A comparison of surgically induced astigmatism and refractive outcomes between the new Clareon toric IOL with AutonoMe injector and the Acrysof IQ toric IOL with Monarch III injector

Poster Details

First Author: B.LaHood NEW ZEALAND

Co Author(s):                        

Abstract Details

Purpose:

The Clareon toric IOL has recently been released in combination with the AutonoMe injector. This is a new material delivered via a unique automated injector. This study will be the first to assess the surgically induced astigmatism (SIA), refractive outcomes, rotational stability and incision architecture of this new combination and compare these measures with the existing Alcon Acrysof IQ toric IOL delivered via a Monarch III injector.

Setting:

Eye Institute private practice, Auckland, New Zealand

Methods:

All patients requiring toric IOL implantation were allocated to receive either the Clareon toric IOL via AutonoMe injector or Acrysof IQ toric IOL via Monarch III injector. At the time of writing, 8 eyes have been implanted with Clareon toric IOLs and 16 eyes implanted with Acrysof IQ toric IOLs. All IOLs were implanted via a 2.2mm wound assisted technique. IOL rotation was assessed based on intraoperative images and post-op photos. OCT of wound architecture were made at 1 day, 1 week and 6 weeks post-op. Keratometry was repeated at 6 weeks post-op for SIA assessment and accurate refraction performed.

Results:

The Clareon toric group showed superior refractive outcomes with 100% of cases within +/-0.5D of zero residual astigmatism. Anterior keratometric mean absolute SIA was 0.18D in the Clareon group and 0.31D in the Acrysof IQ group. Total keratometric and posterior SIA were similar. Post-operative toric IOL rotation was less than one degree on average in both groups with no rotation after day 1 post-op reported in either group. Incision hydration was required at the end of the case less frequently in the Clareon/AutonoMe group (12.5%) compared to the Acrysof IQ/Monarch III group (75%). OCT assessment of incision architecture showed less disruption to normal anatomy in the Clareon/AutonoMe group and a faster recovery compared to the Acrysof IQ/Monarch III group.

Conclusions:

This preliminary data indicates that the Clareon toric/AutonoMe combination via a wound-assisted 2.2mm incision provides superior astigmatic correction and reduced SIA compared to using Acrysof IQ toric/Monarch III. Both toric IOLs showed excellent rotational stability. Eyes treated with Clareon toric/AutonoMe experienced less change to corneal incision anatomy and these changes normalized faster than eyes treated with the Acrysof IQ/Monarch III. This may in part be due to less need for corneal wound hydration in the Clareon group. All of these observations indicate that Clareon toric IOLs via AutonoMe will provide more predictable astigmatic refractive outcomes compared to Acrysof IQ toric IOLs via Monarch III.

Financial Disclosure:

None